Bayer's Pipeline Picks Up Speed: From Olema Oncology Pact to Kerendia's China Expansion, Debt Remains the Drag

Bayer partners with Olema for prostate cancer combo, wins China and FDA approvals for finerenone and asundexian, but debt and glyphosate litigation weigh on stock.

Bayer is quietly broadening its pharmaceutical arsenal on multiple fronts. The latest move: a research collaboration with Olema Pharmaceuticals aimed at testing a new combination therapy for advanced prostate cancer. The partnership, focused on a Phase 1b/2 trial involving around 36 patients, will evaluate Olema's candidate OP-3136 alongside Bayer's own Nubeqa (darolutamide) in men with metastatic castration-resistant prostate cancer where standard treatments have failed. Olema is handling the clinical work while Bayer supplies Nubeqa, and Olema retains all global commercialization and exclusivity rights for OP-3136. The deal is modest in scale but signals Bayer's intent to squeeze more value from its oncology franchise.

That oncology bet comes as Bayer's broader drug pipeline gathers regulatory velocity. The company's star asset, the mineralocorticoid receptor antagonist finerenone (marketed as Kerendia), has been racking up approvals. On May 22, China's NMPA cleared Kerendia for heart failure patients with mildly reduced or preserved ejection fraction — an expansion that opens up roughly 60% of the 13 million Chinese heart failure sufferers to the drug, beyond its earlier kidney disease indication. Meanwhile, the FDA has accepted a priority review application for finerenone in chronic kidney disease associated with type 1 diabetes, cutting the review timeline from ten to six months. The submission is backed by the Phase III FINE-ONE study, which showed a 25% improvement in a key kidney endpoint versus placebo. Adding to the regulatory momentum, Bayer's oral Factor XIa inhibitor asundexian, designed to prevent ischemic stroke, also snagged FDA priority review after the OCEANIC-STROKE trial demonstrated a 26% reduction in ischemic strokes without raising the risk of major bleeding.

The early commercial results reinforce the pipeline's promise. Kerendia's first-quarter revenue surged 84% on a currency- and portfolio-adjusted basis, while Nubeqa climbed 57%. Group revenue for Q1 reached €13.4 billion, with adjusted EBITDA rising 9% to €4.5 billion. Yet the operational strength is almost matched by structural headwinds. Patent expiries on Xarelto and generic competition for Eylea continue to weigh on the portfolio. More pressingly, Bayer's balance sheet carries net financial debt of €32.5 billion as of March 31. Free cash flow swung to negative €2.3 billion, hammered by roughly €2 billion in settlement payments tied to PCB and glyphosate litigation.

Investors have responded with patience, but not enthusiasm. Bayer's stock currently trades around €37.95, nearly flat on the day but down roughly 3.5% over the past seven days — well below the 52-week high of €49.17 reached in February. The legal overhang remains the dominant drag. In the U.S., constitutional concerns have been raised about the proposed $7.25 billion glyphosate settlement. In Brazil, legislative efforts to ban the herbicide are adding fresh uncertainty. On the other side, Bayer's clinical foundation for finerenone rests on five completed Phase III trials involving more than 20,000 patients — a data set that Christine Roth, Executive Vice President of Global Product Strategy, calls a substantial edge.

The next key date for the market is August 4, 2026, when Bayer reports second-quarter results. For the full year, analysts currently project adjusted earnings per share of €4.37. Whether the pipeline's accelerating narrative can eventually overshadow the €32.5 billion debt pile and persistent legal risks will likely define the stock's trajectory in the quarters ahead.